Royce & Associates LP Has $9.52 Million Holdings in RadNet, Inc. $RDNT

Royce & Associates LP lessened its holdings in shares of RadNet, Inc. (NASDAQ:RDNT) by 6.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,859 shares of the medical research company’s stock after selling 8,730 shares during the quarter. Royce & Associates LP owned approximately 0.16% of RadNet worth $9,516,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. WCM Investment Management LLC grew its stake in shares of RadNet by 32.6% in the 3rd quarter. WCM Investment Management LLC now owns 285,778 shares of the medical research company’s stock valued at $21,348,000 after buying an additional 70,244 shares in the last quarter. Castleark Management LLC raised its position in RadNet by 241.7% during the second quarter. Castleark Management LLC now owns 96,203 shares of the medical research company’s stock valued at $5,475,000 after acquiring an additional 68,050 shares in the last quarter. Norges Bank acquired a new stake in RadNet in the second quarter valued at approximately $31,051,000. Penserra Capital Management LLC lifted its stake in RadNet by 43.4% in the third quarter. Penserra Capital Management LLC now owns 479,077 shares of the medical research company’s stock valued at $36,510,000 after acquiring an additional 144,897 shares during the last quarter. Finally, New York State Teachers Retirement System grew its position in RadNet by 53.1% in the third quarter. New York State Teachers Retirement System now owns 30,855 shares of the medical research company’s stock worth $2,351,000 after acquiring an additional 10,700 shares in the last quarter. 77.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RDNT has been the topic of a number of recent research reports. Raymond James Financial restated a “strong-buy” rating on shares of RadNet in a report on Thursday, December 18th. Jefferies Financial Group reissued a “buy” rating and set a $91.00 target price on shares of RadNet in a research report on Tuesday. Barclays raised their target price on RadNet from $79.00 to $86.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of RadNet in a research report on Monday, December 29th. Finally, Truist Financial set a $90.00 price target on RadNet in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $90.43.

Trending Headlines about RadNet

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet announced the acquisition of Gleamer (priced up to €230M / ~$269–270M), integrating the Paris‑based radiology AI vendor into its DeepHealth unit to create the largest clinical radiology AI provider worldwide; management expects material ARR and product breadth gains. RadNet Acquires Gleamer (Business Insider)
• Positive Sentiment: RadNet reported record Q4 revenue and adjusted EBITDA, beat EPS and top‑line estimates (Q4 revenue ~$547.7M; EPS $0.23 vs $0.19 consensus) and highlighted a strong digital health segment (digital revenue reported up ~48%), supporting growth expectations. RadNet Reports Fourth Quarter 2025 Results (GlobeNewswire)
• Neutral Sentiment: Management issued FY‑2026 revenue guidance (~$2.5B vs. ~$2.3B consensus) — a bullish signal for growth but guidance includes forward‑looking assumptions tied to DeepHealth scale‑up and Gleamer integration. Q4 Results & 2026 Guidance (GlobeNewswire)
• Neutral Sentiment: Management is engaging investors: CFO presenting at Raymond James conference and RadNet scheduled an investor call and webcast to discuss the Gleamer deal and Q4 results — good opportunities for further detail on expected synergies and financing. Raymond James Presentation (GlobeNewswire)
• Negative Sentiment: The Gleamer purchase is an all‑cash deal (plus milestones) of up to €230M — this raises near‑term cash/debt and execution risk (integration, realization of projected ARR to ~$140M by year‑end 2026). Investors will watch capital allocation, near‑term leverage and cash flow impact. Acquisition Details & Risks (QuiverQuant)
• Negative Sentiment: While revenue and some metrics beat estimates, RadNet still reported a small negative GAAP net margin and has meaningful integration and execution uncertainties; additional disclosure on cost synergies and timelines remains critical. Earnings Call Transcript (Seeking Alpha)

RadNet Stock Performance

NASDAQ:RDNT opened at $72.58 on Wednesday. The firm has a market capitalization of $5.60 billion, a PE ratio of -290.32 and a beta of 1.49. RadNet, Inc. has a 1 year low of $45.00 and a 1 year high of $85.84. The company has a current ratio of 1.87, a quick ratio of 1.87 and a debt-to-equity ratio of 0.82. The firm’s fifty day simple moving average is $71.67 and its 200 day simple moving average is $74.45.

RadNet (NASDAQ:RDNT) last released its earnings results on Monday, March 2nd. The medical research company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.04. The firm had revenue of $547.71 million during the quarter, compared to analyst estimates of $515.67 million. RadNet had a negative net margin of 0.91% and a positive return on equity of 2.60%. The business’s revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.22 EPS. On average, sell-side analysts anticipate that RadNet, Inc. will post 0.56 EPS for the current year.

RadNet Company Profile

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.